CSL IMPACT REPORT 2026 | 5 POLIO TRIUMPH Just a few short months after Salk's breakthrough in the U.S., CSL issues its first batches of polio vaccine. As a result of vaccination, polio is virtually eliminated in Australia within a number of years. 1956 CSL GOES PUBLIC CSL debuts on the Australian Stock Exchange as a public company. 1994 A FIRST FOR FLU Seqirus successfully commercialises the manufacturing process at its Holly Springs U.S. facility and launches the world’s first four-strain, cell culturederived influenza vaccine. 2016 HAEMOPHILIA HELP CSL issues its first clotting factor treatment for haemophilia A patients in Australia. It also commences plasma fractionation for New Zealand, followed later by Hong Kong, Malaysia, Singapore and Taiwan. 1961 FIRST HPV VACCINE WINS APPROVAL The FDA approves the world's first HPV vaccine for the prevention of cervical cancer and genital warts. It is subsequently launched in major markets around the world, vastly reducing the burden of HPV-related disease. 2006 RECOMBINANT SUCCESS CSL’s first novel recombinant therapies to treat haemophilia are approved in the U.S. 2016 TECHNICAL EXPERTISE IN FLU CSL begins to adapt (re-assort) influenza strains so they grow better in eggs. The resulting 'manufacturing seeds' are provided to the WHO each season, who in turn shares them with all manufacturers for vaccine production. 1973 NEXT GENERATION IVIG CSL Behring launches the first liquid intravenous immunoglobulin able to be stored at room temperature. It quickly becomes CSL Behring's leading product globally. 2007 CELL THERAPY CSL launches its first cell and gene therapy product, which offers patients previously unheard of potential for a functional cure for haemophilia B. 2022 PROTECTING NEWBORNS In a world first, CSL issues Rhesus (D) immunoglobulin. Produced from plasma, it prevents haemolytic disease in newborns due to Rh factor incompatibility. 1967 NEW TREATMENT APPROVED FOR HAE The FDA approves the first treatment in the U.S. for acute abdominal or facial attacks associated with hereditary angioedema (HAE), a rare and serious genetic disorder. It also achieves approval in 20 European countries and the label later expands to include self-administration. 2009 FIRST IN CLASS A first-in-class monoclonal antibody is launched globally offering convenient monthly prophylactic dosing to prevent hereditary angioedema (HAE) attacks. 2025 Q FEVER VACCINE FIRST Based on the work of Professor Barrie Marmion, CSL launches a Q fever vaccine. It becomes a product of national significance in Australia, protecting people who work with livestock. It remains the only vaccine of its kind available. 1988-89 PLASMA CENTRE OF THE FUTURE CSL Plasma opens its first Centre of the Future in Kansas City, Missouri, U.S. The result of three years of design and development work, the model provides a blueprint for enhancing the donor experience and improving operational efficiencies. 2010
RkJQdWJsaXNoZXIy MjE2NDg3